CN Mobile Logo


Breast Cancer

Too Many DCIS Patients Get Axillary Lymph Node Dissection

No benefit of axillary lymph node evaluation has been shown for women with DCIS, yet this lymph node analysis is still often performed in these patients. Image © Blamb / Shutterstock.com.

Breast Cancer

A pair of studies suggest that aromatase inhibitors and bisphosphonates can each improve survival for postmenopausal women with early breast cancer.

Two trials reported marginal or no improvement in survival with nodal irradiation in early breast cancer patients, though reductions were seen in recurrence.

Researchers have discovered that using progesterone in the treatment of breast cancer could result in better clinical outcomes.

Here, we provide an in-depth review of the current evidence for the addition of ovarian suppression to adjuvant endocrine therapy, and we offer recommendations for clinical management.

With the presentation and publication of the TEXT and SOFT trials in 2014, along with the aTTom and ATLAS trials in the last few years, deciding among the standard adjuvant endocrine therapy options for premenopausal women with hormone-sensitive breast cancer has become increasingly complicated.

For breast cancer specialists, much of the excitement at ASCO revolved around the emerging field of checkpoint inhibition in breast cancer and other tumors; however, there were four non-checkpoint presentations in breast cancer that also proved provocative.

[18F]FDG-PET/CT could predict response in patients with metastatic HER2-positive breast cancer treated with lapatinib plus trastuzumab.


Subscribe to Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.